Twist Bioscience and LakePharma Form Strategic Collaboration to Provide Antibody Discovery and Development ServicesAdded On: 2019-04-04
LakePharma Launches GMP Manufacturing of Recombinant Proteins and Antibodies in the Bay AreaAdded On: 2019-04-02
LakePharma Announces Dedicated Vector Center to Support Gene and Cell TherapyAdded On: 2019-02-26
Added On: 2016-04-22
LakePharma's CEO Hua Tu will present at PEGS Boston on Tuesday April 26, 2016.
Dr. Tu will share data for the design, engineering, bioanalytical characterization and manufacturability assessment of Fc fusions and bispecific antibodies.
Company scientists will also present a poster detailing a tandem mass spectrometry approach to proteomic sequencing that enables the accurate determination of an antibody’s primary sequence when the source hybridoma is unavailable. In addition to revealing the full sequence of an important antibody, their approach enabled the engineering of the antibody to improve its production by CHO cells, as well as its performance as a purification reagent.
Details on Poster Sessions